Fatima Rodriguez, MD, MPH is an Associate Professor in Cardiovascular Medicine and (by courtesy) the Stanford Prevention Research Center. Dr. Rodriguez earned her medical degree from Harvard Medical School and her MPH from the Harvard School of Public Health. She then completed internal medicine residency at Brigham and Women’s Hospital and fellowship in cardiovascular medicine at Stanford University. She currently serves as the Section Chief of Preventive Cardiology. Dr. Rodriguez specializes in cardiovascular disease prevention, inherited lipid disorders, and cardiovascular risk assessment in high-risk populations. Dr. Rodriguez’s research includes a range of topics around racial, ethnic, and gender disparities in cardiovascular disease prevention, developing novel interventions to address disparities, and opportunistic screening of coronary artery disease.

Abha Khandelwal is an imaging cardiologist who has clinical experience in cardio-obstetrics, structural disease and prevention of cardiovascular disease in high risk populations. She has a Master’s in Management of Information Systems and has integrated technology to improve operations within the cardiovascular ambulatory clinics. She serves as the Ambulatory Clinic Chief for Cardiovascular Medicine and the General Cardiology Section Lead. Her research spans clinical trials in preventative cardiology, imaging, cardio-obstetrics and women’s heart health. She is the cardiac director of the maternal heart program in collaboration with Maternal Fetal Medicine and Anesthesia. She has participated in a broad range of phase II- phase III clinical trials targeting treatment of elevated lipoprotein a for secondary prevention of cardiovascular disease, diabetes control in cardiovascular disease and dyslipidemia in high risk populations. She has worked within the Stanford South Asian Translational Heart Initiative (SSATHI) program looking at technology utilization to improve adherence to care plans in the south Asian population. She is the course director for the first annual CME for transforming cardiac rehab in the fall at Stanford. She has utilized digital health initiatives to improve cardiometabolic profile of women with history of gestational diabetes and hypertension post-partum. She is an active member in the AHA go red scientific advisory committee and helped with virtual enrollment for their initiatives. As Ambulatory Clinic Chief, she has worked at operationalizing mobile technology within the clinics and used remote patient monitoring to improve patient outcomes. Her vision is to integrate technology to improve health care delivery, health in high-risk populations, and reduce health disparities.

Dr. Maron is the C.F. Rehnborg Professor of Medicine at Stanford University School of Medicine. He received his undergraduate degree from Stanford and his medical degree from the University of Southern California. He trained in internal medicine at UCLA. He returned to Stanford where he was a Robert Wood Johnson Clinical Scholar, a preventive cardiology fellow at the Stanford Prevention Research Center, and remained at Stanford to complete a cardiology fellowship. After a brief stint in private practice in Santa Monica, he joined the faculty at Vanderbilt University School of Medicine as Assistant Professor and Director of Preventive Cardiology in 1993, and rose through the ranks to Professor. In 2014 he returned to Stanford where he serves as Chief of SPRC. Dr. Maron sees patients in the Preventive Cardiology Clinic. His research interests include primary and secondary prevention of coronary artery disease. As a fellow at SPRC, he was introduced to clinical research as a member of the team that conducted the Stanford Coronary Risk Intervention Project. He applied lessons learned from that experience to the design of the landmark COURAGE trial, for which he served as the chairman of the optimal medical therapy committee. He went on to be principal investigator and co-chair of the ISCHEMIA trial, an NIH-funded study comparing the effectiveness of two initial management strategies – invasive (optimal medical therapy plus cardiac catheterization and revascularization with stents or bypass surgery) versus conservative (optimal medical therapy alone) – in approximately 5,000 patients with stable coronary artery disease and at least moderate ischemia on a stress test. There was no overall statistical difference in major clinical endpoints in ISCHEMIA, but patients with angina had better symptom relief with invasive management. COURAGE and ISCHEMIA have had a major impact on the management of stable coronary disease around the world, with both trials emphasizing the importance of lifestyle and appropriate medications to control risk factors and prevent heart attacks and death. Dr. Maron’s current research involves early detection of subclinical coronary disease in people without a diagnosis of heart disease. One method that he is investigating is using an artificial intelligence algorithm that he helped develop to measure calcified plaque in coronary arteries from a chest CT scan done for other purposes. His team has shown that detection and notification of patients and their clinicians about the presence of coronary calcium dramatically increases the use of statins as recommended by guidelines. Another method he is investigating is the use of noninvasive coronary CT angiograms to guide the management of patients at increased risk of heart disease as compared with strictly relying on risk factors. With these projects he hopes to transform the methods commonly used to prevent heart attacks. Dr. Maron is president-elect of the American Society for Preventive Cardiology.

Eleanor Levin completed her undergraduate degree at Stanford, Phi Beta Kappa in Human Biology with Distinction, and her MD at UCSF as a Phi Beta Kappa Scholar. Her first internship was at Children's Hospital of San Francisco in pediatrics and her second at the Cleveland Clinic in internal medicine. She completed internal medicine training at Georgetown University and cardiology fellowship at George Washington University in Washington, D.C. At GW she undertook an advanced fellowship in echocardiography and lipids following her general cardiology fellowship. After fellowship training, Dr. Levin joined the GW faculty as an assistant professor of medicine in the Lipid Research Clinic. Subsequently she joined The Permanente Medical Group in northern California as a non-invasive cardiologist. She directed the Echocardiography Lab at Kaiser Santa Clara and introduced TEE and stress echo during her 25-year tenure. She introduced CT angiography of the heart at Santa Clara and coordinated joint readings between Radiology and Cardiology for 15 years. She created the Cholesterol Management and Heart Failure Programs initially at Santa Clara and eventually at more than 20 medical centers in Northern California. She was Kaiser's regional expert in lipidology as well as in cardiac disease in pregnancy in a patient population of 4 million. Dr. Levin served as Chief of Cardiology at Santa Clara for 14 years and as Chair of the Chiefs of Cardiology (120 cardiologists) for Northern California Kaiser for 8 years. She directed the Regional Cardiac Rehabilitation Program using home-based comprehensive rehabilitation across 18 medical centers for nearly three decades. During this time, she led teams developing cardiac guidelines embedded in order sets and electronic medical records throughout Kaiser medical centers to improve quality. She has spoken about and presented her work on population management and quality improvement nationally and internationally. Her awards include the national NCQA (National Committee of Quality Assurance) Award for Excellence in Cardiac Care, the Exceptional Contribution Award from The Permanente Medical Group for “exceptional work in care management programs” for heart failure and cholesterol management, the Santa Clara County Medical Association Outstanding Achievement Award for cardiac care management, and the Silicon Business Journal Award as one of the "Top 100 Influential Women in Silicon Valley." She is a fellow of the American College of Cardiology and the American Heart Association. She is board certified in both Internal Medicine and in Cardiovascular Diseases by the American Board of Internal Medicine. She joined the Stanford University School of Medicine as a Clinical Professor in 2018 after decades as Voluntary Affiliate Faculty at Kaiser Santa Clara. Currently she teaches medical students, medical residents, and Cardiology fellows, as well as directing the Stanford undergraduate shadowing program. She conducts collaborative research in cardio-obstetrics, Value Based Care, and cardiac rehabilitation. Dr. Levin is a member of the Preventive Cardiology group. She consults on pregnant patients with heart disease as well as general cardiology patients with lipid disorders and a broad range of cardiovascular diseases.

Dr. Fahim Abbasi specializes in diagnosis and treatment of prediabetes and insulin resistance. Dr. Abbasi has a special interest in prevention of diabetes and cardiovascular disease through lifestyle modifications.

I am a physician-scientist and the overall theme my research has been the genetic basis of cardiovascular disease across the continuum from Discovery to the development of Model Systems to the Translation of these findings to the clinic and most recently to the Public Health aspect of genetics. I completed his MD-PhD at UNC with Prof. Nobuyo Maeda and Nobel Laureate Oliver Smithies. I did Internal Medicine residency and Cardiology fellowship training at Stanford working with Dr. Tom Quertermous. Currently my Discovery and basic translational efforts center on understanding the genetic basis of insulin resistance using GWAS studies coupled with exploration in model systems including iPSCs and CRISPR screens. My clinical translational focus is on Familial Hypercholesterolemia (FH) and I am the volunteer Chief Research Advisor of the Family Heart Foundation (FHF) which is a patient-led organization dedicated to increasing awareness of FH, identifying and treating patients with FH and screening family members to prevent deleterious outcomes. I helped lead the FHF efforts to establish a national patient registry (CASCADE FH), apply for an ICD10 code for FH and using cutting-edge “big-data” approaches to identify previously undiagnosed FH patients in electronic medical records (FIND FH). I have published over 120 papers with research projects currently funded by the National Institutes of Health, the American Diabetes Association, the American Heart Association and the Doris Duke Charitable Foundation.

Latha Palaniappan MD, MS, is an internist, and clinical and population researcher. Her research has focused on the study of diverse populations, chronic disease and prevention. Dr. Palaniappan specifically seeks to address the gap in knowledge of health in Asian subgroups and other understudied racial/ethnic minorities (PACS 5R01DK081371, CASPER R01HL126172, and CAUSES R01MD007012). Her current work examines the clinical effectiveness of structured physical activity programs for diabetes management (Initiate and Maintain Physical Activity in Clinics - IMPACT, 5R18DK096394), as well as best exercise regimens for normal-weight diabetics (Strength Training Regimen for Normal Weight Diabetics - STRONG-D, 2R01DK081371). She was recently awarded a Midcareer Investigator Award (K24 HL150476) by the National Institutes of Health to provide mentoring to junior clinical investigators in the conduct of patient oriented research. She is currently working on implementation of evidence based genetic and pharmacogenetic testing in clinical settings. She received a Fulbright Award in 2022 to work with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) on implementation of Precision Health in Australia. Dr. Palaniappan is the Faculty co-Director of the Stanford Biobank (with Drs. Brooke Howitt and Joachim Hallmayer) designed to accelerate translatable scientific discoveries. She co-founded (with Dr. Bryant Lin) the Center for Asian American, Native Hawaiian and Pacific Islander Health Research and Education (CARE) at Stanford in 2018.

Dr. McConnell is a native of Brooklyn, NY and attended the Massachusetts Institute of Technology, obtaining his BS and MS in Electrical/Biomedical Engineering, followed by his MD at Stanford University. He returned to Boston and specialized in Cardiovascular Medicine and Cardiovascular Imaging at Brigham and Women’s and Beth Israel Hospitals and then joined the faculty at Harvard Medical School, where he also obtained an MS in Clinical Investigation. His early research discovery in echocardiography has become known as “McConnell’s sign.” He joined the faculty at Stanford in 1998 and went on to become Professor of Cardiovascular Medicine and (by courtesy) Electrical Engineering and Molecular & Cellular Physiology. He was Director of Cardiovascular MRI, Preventive Cardiology Clinic, and Cardiovascular Health Innovation at Stanford and also founded and directed the Cardiovascular Imaging at Stanford (CVIS) NIH training program. He was the Principal Investigator for multiple NIH and American Heart Association (AHA) research grants as well as the top-enrolling MyHeart Counts mobile health research study launched with Apple. In 2015 he joined Google/Alphabet leading cardiovascular and digital health projects, including development, validation, and FDA clearances for mobile/wearable devices and AI software with Verily, Google Health, and Fitbit. He is now the Chief Health Officer at Toku to advance AI and retinal imaging for screening and prevention of major health conditions. Dr. McConnell continues to see patients in the Stanford Preventive Cardiology Clinic and mentor in the Stanford Biodesign program. He has published over 130 peer-reviewed articles and is a Fellow of the AHA, the American College of Cardiology (ACC), the Society for Cardiovascular Magnetic Resonance, and the American Society of Echocardiography. He is a founding member of the AHA’s Health Technologies Advisory Group and co-chaired AHA’s 2030 Impact Goal task force and the ACC-Consumer Technology Association’s guidance on Cardiovascular Technology Solutions. In 2022, Dr. McConnell was appointed by the Secretary of the U.S. Department of Health and Human Services to the Board of Directors of the National Fitness Foundation. His book, Fight Heart Disease Like Cancer, was published by Hopkins Press in January 2024.

Neil Kalwani, MD, MPP is a Clinical Instructor in the Division of Cardiovascular Medicine and Director of Preventive Cardiology at the VA Palo Alto Health Care System. He attended college at Yale University and completed graduate degrees in medicine and public policy at Harvard University. He trained in internal medicine at Brigham and Women’s Hospital before arriving at Stanford in 2018 for fellowship in cardiovascular medicine, during which he served as Chief Fellow. He then completed a postdoctoral fellowship through the Stanford-AHRQ Health Services Research Training Program in the Department of Health Policy. His clinical focus is in general and preventive cardiology and echocardiography. He practices at the VA Palo Alto Health Care System and at Stanford Health Care. Dr. Kalwani's research focuses on the evaluation of policies and care delivery innovations designed to improve the value of care for patients with cardiovascular disease.

Dr. Dudum is a cardiologist and population health expert working to develop novel risk prediction methods and implementation strategies to create practices and systems that allow for reductions in cardiovascular disease. He completed a Masters in Public Health at Johns Hopkins concentrating in epidemiology and biostatistics and a Doctorate of Medicine at George Washington University. He completed internal medicine residency training as part of the Osler Medical Service, where he worked under the mentorship of Drs. Roger Blumenthal and Michael Blaha to study improving cardiovascular risk prediction and coronary artery calcium. Given his focus on population health and implementation science, he also helped launch and refine risk adjustment tools and implemented guideline-directed medical care pathways. During his time there, he was recognized for his clinical acumen and dedication to patient care. He came to Stanford for his cardiovascular medicine fellowship and continued research in coronary artery calcium under the mentorship of Drs. David Maron and Fatima Rodriguez while also conducting cardiovascular health implementation science work under the mentorship of Dr. Steve Asch. He serves as the co-investigator of a prospective randomized trial testing the effects of notification of incidental coronary artery calcium on statin initiation rates among those with and without cardiovascular disease (NCT 05588895). He has worked with hospital leaders to implement digital health and artificial intelligence tools, creating the infrastructure for the prospective use of AI-algorithms on radiology studies. As a preventive cardiologist and population health expert, he leads efforts in the preventive cardiology section related to improving cardiovascular health.

Dr. Clarke is a preventive cardiologist and a physician-scientist focused on disease prevention. He earned his undergraduate degree in human biology from the Division of Nutritional Sciences at Cornell University before obtaining his MD and PhD (genetics) from Stanford University School of Medicine. He has completed clinical training in internal medicine (Brigham & Women’s Hospital), pediatrics (Boston Children’s Hospital), and cardiovascular medicine (Stanford Hospital), and he is board certified in all three specialties. His research is focused on 1) understanding complex disease genetics in diverse populations, 2) integrating monogenic and polygenic risk with clinical risk, 3) large-scale phenotyping using the electronic health record and medical images. His clinical practice focuses on identifying risk factors for cardiovascular disease with the goal of promoting health and longevity through evidence-based personalized treatment. He is interested in developing family-centric approaches for the treatment of adults and children carrying genetic risk for disease.

Dr. Sneha S. Jain is a Clinical Assistant Professor in the Division of Cardiovascular Medicine. She specializes in general cardiovascular medicine and preventive cardiology. She received her MD from the Johns Hopkins School of Medicine and her MBA from Harvard Business School. She graduated with distinction from Duke University with a BS in Economics. She completed internal medicine resident training at Columbia/NewYork-Presbyterian, during which time she was selected as a Silverman Fellow in Healthcare Innovation. In this capacity, she worked with clinical and data science partners to build and deploy the technological infrastructure to identify patients with certain cardiac conditions earlier in the course of their disease. She subsequently pursued fellowship training in cardiovascular medicine at Stanford University prior to joining faculty. Her research focuses on the development and responsible evaluation of AI to augment healthcare delivery and improve patient outcomes in cardiology. She works with the Stanford Center for Clinical Research and the Data Science Team at Stanford to deploy and prospectively evaluate AI solutions across the healthcare enterprise.

Rupan Bose, MD, MB, is a Cardiologist and Clinical Assistant Professor in the Division of Cardiovascular Medicine at Stanford. He specializes in Preventive Cardiology, with a particular focus on high-risk populations. Dr. Bose completed his medical degree from the Keck School of Medicine of USC. He then completed his internal medicine residency at USC, followed by his fellowship in cardiovascular medicine at Harbor-UCLA. He also has a particular interest in the intersection of medicine and technology, and he holds Masters in Biotechnology (MB) with an emphasis on Bioinformatics from the University of Pennsylvania. His research interests are investigating the underlying cardiovascular drivers of risk in high-risk ethnic groups, as well as investigating the role of emerging technologies and innovations in promoting cardiovascular disease monitoring and outcomes. At Stanford, Dr. Bose serves in the Preventive Cardiology clinic and the Stanford South Asian Translational Heart Initiative (SSATHI) clinics, as well as in the inpatient cardiovascular services.